Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETBX-021
- Development stage
- Discontinued
- Lead developer
- NantBio
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Subcutaneous
01
Overview
ETBX-021 is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack tumor cells expressing the HER2 protein. It uses a genetically modified adenovirus type 5 (Ad5) vector with deletions in the E1 and E2b regions to deliver the HER2 gene, prompting an immune response specifically against HER2-expressing cancer cells. The vaccine aims to induce cytotoxic T-cell responses targeting tumors that overexpress or express low levels of HER2, such as certain breast cancers. Originally developed by Etubics Corporation and later advanced by NantBioScience and ImmunityBio, its clinical development has been discontinued after early-phase trials in breast cancer due to low enrollment[1][3][5].
- Other names
- Ad5 [E1-, E2b-]-HER2/neu VaccineETBX 021ETBX021ETBX-021
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ETBX-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETBX-021.